Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Psychiatric Quarterly
Published in: Psychiatric Quarterly 1/2020

01-03-2020 | Affective Disorder | Original Paper

Prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Depression among Adults with Inflammatory Chronic Conditions in the United States

Authors: Nazneen Fatima Shaikh, Usha Sambamoorthi

Published in: Psychiatric Quarterly | Issue 1/2020

Login to get access

Abstract

The association of prescription NSAIDs to presence of depression among adults with inflammatory chronic conditions in adults with and without depression and seeking care in routine clinical practice remains unknown. We examined the association of prescription NSAIDs to depression among adults with inflammatory chronic conditions in a nationally representative sample of the US non-institutionalized civilian population. We used a retrospective cross-sectional design. Data on 10,713 adults with inflammatory chronic conditions were derived from 2015 Medical Expenditure Panel Survey (MEPS). The dependent variable was the presence or absence of depression and the key independent variable was prescription NSAIDs use. Logistic regression models were used to examine the adjusted associations of prescription NSAIDs to depression. In these regressions, other independent variables (biological, sociocultural, socio-economic, access to healthcare services, medical conditions and treatment factors, behavioural, and environmental factors) that may affect the relationship of prescription NSAIDs to depression were also included. All analyses accounted for the complex survey design of MEPS. Overall, 18.2% reported depression. Almost 21% used prescription NSAIDs. In the unadjusted model, prescription NSAIDs use had higher odds of depression (OR = 1.59;95%CI = [1.40, 1.82]) as compared to those without NSAIDs. In the fully-adjusted logistic regression model, with controls for other independent variables, adults using prescription NSAIDs had no significant association with depression (AOR = 0.97;95%CI = [0.84, 1.13]) compared to those without NSAIDs. In this first real-world study of all adults (with and without depression) in the US, we did not observe a statistically significant association of prescription NSAIDs to the presence of depression.
Literature
1.
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34.PubMedPubMedCentral
2.
Kopschina Feltes P, Doorduin J, Klein HC, Juárez-Orozco LE, Dierckx RA, Moriguchi-Jeckel CM, et al. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J Psychopharmacol. 2017;31(9):1149–65.PubMedPubMedCentral
3.
Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35(4):298–306.
4.
Kohler O, Krogh J, Mors O, Eriksen Benros M. Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol. 2016;14(7):732–42.PubMedPubMedCentral
5.
Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–41.PubMedPubMedCentral
6.
Au B, Smith KJ, Gariépy G, Schmitz N. The longitudinal associations between C-reactive protein and depressive symptoms: evidence from the English longitudinal study of ageing (ELSA). Int J Geriatr Psychiatry. 2015;30(9):976–84.PubMed
7.
Gimeno D, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2009;39(03):413.PubMed
8.
Dahl J, Ormstad H, Aass HC, Malt UF, Bendz LT, Sandvik L, et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. Jul. 2014;45:77–86.PubMed
9.
Iyengar RL, et al. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med. 2013;126(11):1017.e11–8.
10.
Köhler O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiat. 2014;71(12):1381–91.
11.
Fields C, Drye L, Vaidya V, Lyketsos C. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry. 2012;20(6):505–13.PubMedPubMedCentral
12.
Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, et al. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry. 2012;169(10):1065–72.PubMedPubMedCentral
13.
Menter A, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62(5):812–8.PubMed
14.
Arana GW, Santos AB, Laraia MT, McLeod-Bryant S, Beale MD, Rames LJ, et al. Dexamethasone for the treatment of depression: a randomized, placebo- controlled, double-blind trial. Am J Psychiatry. Feb. 1995;152(2):265–7.PubMed
15.
K. Park, Park’s textbook of preventive and social medicine-Banarsidas Bhanot | Ayurveda | Medicine. 2015.
16.
17.
18.
19.
20.
21.
Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383–9.PubMedPubMedCentral
22.
Bhattacharya R, Shen C, Sambamoorthi U. Excess risk of chronic physical conditions associated with depression and anxiety. BMC Psychiatry. 2014;14:10.PubMedPubMedCentral
23.
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. Jun. 2001;24(6):1069–78.PubMed
24.
CDC, Mental Health and Chronic Diseases CDC Fact Sheet, 2012.
25.
Davis JS, et al. Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Hear. 2017;4(1):e000550.
26.
Eyre HA, Air T, Proctor S, Rositano S, Baune BT. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog Neuro-Psychopharmacol Biol Psychiatr. 2015;57:11–6.
27.
Almeida OP, Alfonso H, Jamrozik K, Hankey GJ, Flicker L. Aspirin use, depression, and cognitive impairment in later life: the health in men study. J Am Geriatr Soc. 2010;58(5):990–2.PubMed
28.
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607–11.PubMed
29.
Abbasi S-H, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012;141(2–3):308–14.PubMed
30.
Pretorius E. Corticosteroids, depression and the role of serotonin. Rev Neurosci. 2004;15(2):109–16.PubMed
31.
32.
Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief. 2010;(42):1–8.
33.
Sutherland JJ, Daly TM, Liu X, Goldstein K, Johnston JA, Ryan TP. Co-Prescription Trends in a Large Cohort of Subjects Predict Substantial Drug-Drug Interactions. PLoS One. 2015;10(3):e0118991.PubMedPubMedCentral
34.
Qato DM, Ozenberger K, Olfson M. Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States. JAMA. 2018;319(22):2289.PubMedPubMedCentral
35.
Glezer A, Byatt N, Cook R, Rothschild AJ. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic. J Affect Disord. 2009;117(1–2):18–23.PubMed
36.
Casagrande Tango R. Psychiatric side effects of medications prescribed in internal medicine. Dialogues Clin Neurosci. 2003;5(2):155–65.PubMedPubMedCentral
37.
Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007;50(5):470–9.PubMed
38.
Schjerning Olsen A-M, et al. Cause-Specific Cardiovascular Risk Associated with Nonsteroidal Anti-Inflammatory Drugs among Myocardial Infarction Patients - A Nationwide Study. PLoS One. 2013;8(1):e54309.PubMedCentral
39.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–8.PubMedPubMedCentral
40.
Gorton HC, Webb RT, Kapur N, Ashcroft DM. Non-psychotropic medication and risk of suicide or attempted suicide: a systematic review. BMJ Open. 2016;6(1):e009074.PubMedPubMedCentral
41.
Lavigne JE. Suicidal ideation and behavior as adverse events of prescribed medications: an update for pharmacists. J Am Pharm Assoc. 2016;56(2):203–6.
42.
Boal AH, Smith DJ, McCallum L, Muir S, Touyz RM, Dominiczak AF, et al. Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood DisordersNovelty and significance. Hypertension. 2016;68(5):1132–8.PubMedPubMedCentral
43.
Aubin HJ, Tilikete S, Barrucand D. Depression and smoking. Encephale. 1996;22(1):17–22.PubMed
44.
Belle D, Doucet J. Poverty, inequality, and discrimination as sources of depression among U.S. women. Psychol Women Q. 2003;27(2):101–13.
45.
Crystal S, Sambamoorthi U, Walkup JT, Akincigil A. Diagnosis and treatment of depression in the elderly Medicare population: predictors, disparities, and trends. J Am Geriatr Soc. Dec. 2003;51(12):1718–28.PubMedPubMedCentral
46.
Culbertson FM. Depression and gender: an international review. Am Psychol. 1997;52(1):25–31.PubMed
47.
Dimeo F, Bauer M, Varahram I, Proest G, Halter U. Benefits from aerobic exercise in patients with major depression: a pilot study. Br J Sports Med. Apr. 2001;35(2):114–7.PubMedPubMedCentral
48.
Glassman AH, et al. Smoking, Smoking Cessation, and Major Depression. JAMA. 1990;264(12):1546.PubMed
49.
50.
O’Neal HA, Dunn AL, Martinsen. Depression and exercise. Int J Sport Psychol. 2000;31(2):110–35.
51.
Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and Pain Comorbidity: A literature review. Arch Intern Med. 2003;163(20):2433.PubMed
Metadata
Title
Prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Depression among Adults with Inflammatory Chronic Conditions in the United States
Authors
Nazneen Fatima Shaikh
Usha Sambamoorthi
Publication date
01-03-2020
Publisher
Springer US
Published in
Psychiatric Quarterly / Issue 1/2020
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-019-09693-6

Other articles of this Issue 1/2020

Psychiatric Quarterly 1/2020 Go to the issue

Original Paper

The Relationship Between Anxiety, Depression, Suicidal Ideation and Quality of Life in Patients with Rheumatoid Arthritis

Original Paper

Preventing Suicide among Psychiatric Inpatients with Psychotic Depression

Original Paper

The Role of Traumatic Experiences and Posttraumatic Stress on Social Anxiety in a Youth Sample in Lithuania

Original Paper

Adherence to Antidepressant Therapies in Patients with Depressive Disorders Attending an Outpatient Clinic in a Public Mental Health Hospital, Antioquia, Colombia in 2017

Original Paper

Differences in Distress and Utilization of Mental Health Services between 2005 and 2018: a Potential Trend?

Original Paper

A Descriptive Study of United States-Based Human Trafficking Specialty Clinics